Printer Friendly

Vision Pharma steps up development.

WALL, N.J. -- Vision Pharma LLC says it has signed an exclusive formulation and research and development agreement with Paul Sudhakar, a former president of Midland Pharmaceuticals LLC and Martec Pharmaceutical LLC.

"Paul will be contracted to work on our growing pipeline of products in our new lab in Kansas City, Kansas," explains Sander Busman, president and chief executive officer of Vision Pharma, based here.

More than 64 formulations are being developed by Sudhakar for which Vision Pharma will be seeking abbreviated new drug application (ANDA) and new drug application (NDA) approvals, according to Busman.

"Worldwide, Paul has accumulated over 300 formulations and has achieved remarkable success in his career," Busman comments.

"When we blend our skills together, Vision Pharma will gain more control over the development process, reduce major costs and speed FDA approval times," he adds.

Vision Pharma is a generic pharmaceutical company that specializes in niche products with various delivery options and dosage forms.

[ILLUSTRATION OMITTED]

According to the company's web site, Vision Pharma's roster of products includes brompheniramine tannate chewable tablets, 12 mg (60- and 100-count sizes); carisoprodol, 350mg (100-count); colchicine, 0.6 mg (100, 500- and 1,000-count); hyoscyamine sulfate orally disintegrating tablets, 0.125 mg (90- and 100-count); loratadine, 10 mg (100-count); Vis-Phos N (100-count); Visonex (20-count); Visqid A/A (100-count); VisRx Dose Pack 10 (20-count); VisRx Dose Pack 30 (60-count); Vistra 650 (100-count); and Visvex HC Liquid (473 mL).

Through its web site, Vision Pharma also offers VisVoice, an online service that e-mails subscribers the latest news and information from the Food and Drug Administration, including new approvals and recalls.

COPYRIGHT 2009 Racher Press, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

 
Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:RX RETAIL PHARMACY: Generic Drugs; Midland Pharmaceuticals LLC
Publication:Chain Drug Review
Article Type:Brief article
Geographic Code:1USA
Date:May 25, 2009
Words:267
Previous Article:Biogenerics need 'different rules'.
Next Article:Oxycodone relaunched by Actavis.
Topics:

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters